Ralph Loren, a Boston-based partner in Edwards Wildman's
Intellectual Property Department, commented on how drugmaker Teva must wait until 2015 before selling generic versions of Shire’s Intuniv product in World Intellectual Property Review. In the article, "Shire Settles with Teva over ADHD Drug
," Loren said, "The first generic entering the market typically takes about 50 percent of a drug’s market share within the first six months, with this figure soon rising to 80 percent but which is shared between the two generics." According to Loren, brands can still make sizeable sales once generic rivals are selling products, owing to brand loyalty and worries that people might have adverse reactions to non-active compounds in the generic drugs, which don’t have to be completely the same as the original drug’s.